Stoke Therapeutics (NASDAQ:STOK)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a report issued on Monday, AnalystRatings.com reports. They presently have a $30.00 target price on the stock. HC Wainwright’s target price suggests a potential upside of 3.52% from the company’s previous close.

STOK has been the subject of a number of other research reports. JPMorgan Chase & Co. lowered their target price on Stoke Therapeutics from $34.00 to $33.00 and set an “overweight” rating for the company in a research note on Tuesday, December 3rd. BTIG Research initiated coverage on Stoke Therapeutics in a research note on Tuesday, November 12th. They issued a “buy” rating and a $46.00 price target on the stock. Cowen reissued a “buy” rating on shares of Stoke Therapeutics in a research note on Thursday, August 15th. Finally, Zacks Investment Research upgraded shares of Stoke Therapeutics from a “hold” rating to a “buy” rating and set a $23.00 target price on the stock in a report on Wednesday, October 16th. Seven research analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and an average target price of $35.17.

Shares of NASDAQ:STOK opened at $28.98 on Monday. The stock has a fifty day simple moving average of $25.39. Stoke Therapeutics has a 52 week low of $19.21 and a 52 week high of $39.04.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.01. As a group, analysts forecast that Stoke Therapeutics will post -2.08 earnings per share for the current year.

In other news, major shareholder Rtw Investments, Lp acquired 68,783 shares of the stock in a transaction dated Friday, November 1st. The stock was purchased at an average cost of $29.89 per share, with a total value of $2,055,923.87. Insiders acquired 205,216 shares of company stock worth $5,771,421 in the last 90 days.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Platinum Investment Management Ltd. purchased a new position in Stoke Therapeutics during the 2nd quarter valued at about $29,000. Strs Ohio purchased a new stake in Stoke Therapeutics in the 3rd quarter worth approximately $51,000. Victory Capital Management Inc. purchased a new stake in Stoke Therapeutics in the 2nd quarter worth approximately $73,000. Ladenburg Thalmann Financial Services Inc. bought a new stake in shares of Stoke Therapeutics in the 2nd quarter worth approximately $88,000. Finally, Morgan Stanley bought a new stake in shares of Stoke Therapeutics in the 2nd quarter worth approximately $104,000. 48.61% of the stock is currently owned by institutional investors.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001, to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc has a partnership with Invitae Corporation to offer epilepsy panel testing.

Further Reading: What is the Coverage Ratio?

Analyst Recommendations for Stoke Therapeutics (NASDAQ:STOK)

Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.